Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Myeloproliferative Disorders

ClinicalTrials.gov lists 2,227 trials for Myeloproliferative Disorders or a narrower condition beneath it. Novartis Pharmaceuticals has the most among industry and government lead sponsors, with 120.

MeSH D009196 Hemic and Lymphatic Diseases C15
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 426 Phase 1/2 Phase 1/2 204 Phase 2 Phase 2 786 Phase 2/3 Phase 2/3 25 Phase 3 Phase 3 206 Phase 4 Phase 4 45 Not applicable Not applicable 157 Observational Observational 360 Phase 1 Phase 1 426 Phase 1/2 Phase 1/2 204 Phase 2 Phase 2 786 Phase 2/3 Phase 2/3 25 Phase 3 Phase 3 206 Phase 4 Phase 4 45 Not applicable Not applicable 157 Observational Observational 360

Trials per phase (log scale)

2 more sections with rows

663 of the 2,227 trials are tagged with Myeloproliferative Disorders itself; the rest are tagged with a narrower condition beneath it.

Get the Myeloproliferative Disorders report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Myeloproliferative Disorders trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 4 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access, Unknown)

Top of scale: 96

1990: 1 trials (Phase 2 1) 1991: 2 trials (Observational 1, Phase 2 1) 1992: 3 trials (Not applicable 1, Phase 2 2) 1993: 3 trials (Phase 3 1, Phase 2 2) 1994: 8 trials (Phase 3 1, Phase 2 6, Phase 1 1) 1995: 15 trials (Observational 1, Not applicable 1, Phase 3 4, Phase 2/3 1, Phase 2 3, Phase 1/2 3, Phase 1 2) 1996: 16 trials (Observational 1, Phase 3 5, Phase 2 6, Phase 1/2 2, Phase 1 2) 1997: 23 trials (Not applicable 3, Phase 3 4, Phase 2 7, Phase 1/2 2, Phase 1 7) 1998: 41 trials (Observational 2, Not applicable 1, Phase 4 1, Phase 3 7, Phase 2/3 2, Phase 2 17, Phase 1/2 2, Phase 1 9) 1999: 56 trials (Observational 2, Not applicable 4, Phase 3 6, Phase 2/3 2, Phase 2 23, Phase 1/2 4, Phase 1 15) 2000: 60 trials (Observational 1, Not applicable 5, Phase 3 9, Phase 2/3 1, Phase 2 28, Phase 1/2 6, Phase 1 10) 2001: 56 trials (Observational 2, Not applicable 7, Phase 3 1, Phase 2/3 1, Phase 2 30, Phase 1/2 7, Phase 1 8) 2002: 60 trials (Observational 1, Not applicable 5, Phase 3 10, Phase 2 25, Phase 1/2 6, Phase 1 13) 2003: 55 trials (Observational 2, Not applicable 7, Phase 4 2, Phase 3 4, Phase 2 22, Phase 1/2 6, Phase 1 12) 2004: 76 trials (Observational 3, Not applicable 5, Phase 4 1, Phase 3 6, Phase 2/3 2, Phase 2 35, Phase 1/2 9, Phase 1 15) 2005: 95 trials (Observational 4, Not applicable 6, Phase 4 3, Phase 3 8, Phase 2/3 1, Phase 2 37, Phase 1/2 9, Phase 1 27) 2006: 96 trials (Other 2, Observational 9, Not applicable 5, Phase 4 1, Phase 3 7, Phase 2/3 3, Phase 2 41, Phase 1/2 9, Phase 1 19) 2007: 87 trials (Other 1, Observational 11, Not applicable 10, Phase 3 7, Phase 2/3 1, Phase 2 31, Phase 1/2 8, Phase 1 18) 2008: 96 trials (Other 1, Observational 17, Not applicable 4, Phase 4 2, Phase 3 10, Phase 2 29, Phase 1/2 13, Phase 1 20) 2009: 88 trials (Other 1, Observational 15, Not applicable 7, Phase 4 2, Phase 3 8, Phase 2/3 3, Phase 2 29, Phase 1/2 9, Phase 1 14) 2010: 81 trials (Observational 14, Not applicable 6, Phase 4 3, Phase 3 9, Phase 2/3 1, Phase 2 24, Phase 1/2 4, Phase 1 20) 2011: 83 trials (Observational 16, Not applicable 2, Phase 4 1, Phase 3 8, Phase 2 35, Phase 1/2 5, Phase 1 16) 2012: 77 trials (Observational 14, Not applicable 2, Phase 4 2, Phase 3 9, Phase 2/3 1, Phase 2 27, Phase 1/2 8, Phase 1 14) 2013: 77 trials (Observational 14, Not applicable 5, Phase 4 5, Phase 3 4, Phase 2 25, Phase 1/2 12, Phase 1 12) 2014: 83 trials (Observational 17, Not applicable 4, Phase 4 3, Phase 3 14, Phase 2/3 1, Phase 2 24, Phase 1/2 7, Phase 1 13) 2015: 71 trials (Observational 14, Not applicable 6, Phase 4 3, Phase 3 6, Phase 2 23, Phase 1/2 5, Phase 1 14) 2016: 70 trials (Observational 18, Not applicable 2, Phase 4 4, Phase 3 4, Phase 2 21, Phase 1/2 10, Phase 1 11) 2017: 64 trials (Observational 14, Not applicable 8, Phase 4 1, Phase 3 3, Phase 2/3 1, Phase 2 28, Phase 1/2 4, Phase 1 5) 2018: 62 trials (Observational 12, Not applicable 2, Phase 3 4, Phase 2 21, Phase 1/2 5, Phase 1 18) 2019: 74 trials (Observational 15, Not applicable 4, Phase 4 1, Phase 3 8, Phase 2/3 1, Phase 2 26, Phase 1/2 7, Phase 1 12) 2020: 70 trials (Observational 16, Not applicable 3, Phase 3 4, Phase 2 24, Phase 1/2 9, Phase 1 14) 2021: 89 trials (Observational 14, Not applicable 8, Phase 4 3, Phase 3 11, Phase 2 36, Phase 1/2 8, Phase 1 9) 2022: 76 trials (Observational 25, Not applicable 3, Phase 4 3, Phase 3 5, Phase 2 18, Phase 1/2 5, Phase 1 17) 2023: 67 trials (Observational 24, Not applicable 9, Phase 4 1, Phase 3 5, Phase 2 15, Phase 1/2 3, Phase 1 10) 2024: 84 trials (Observational 24, Not applicable 7, Phase 4 1, Phase 3 8, Phase 2 20, Phase 1/2 7, Phase 1 17) 2025: 52 trials (Observational 17, Not applicable 4, Phase 3 1, Phase 2 17, Phase 1/2 5, Phase 1 8)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 83
2025 52
2024 84
2023 67
2022 76
2021 89
2020 70
2019 74
2018 62
2017 64

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 95 trials starting in 2026 and about 69 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 184 trials still running at the 2026-10-09 snapshot; registered median of 42 months across 1,537 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Myeloproliferative Disorders trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 426
Phase 1/2 204
Phase 2 786
Phase 2/3 25
Phase 3 206
Phase 4 45
Not applicable 157
Observational 360
Expanded access 17
Unknown 1

How many Myeloproliferative Disorders trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 57
Recruiting 234
Enrolling by invitation 3
Active, not recruiting 133
Available 5

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Myeloproliferative Disorders trials? (5)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Novartis Pharmaceuticals 120
National Cancer Institute (NCI) 112
Bristol-Myers Squibb 38
Incyte Corporation 34
National Heart, Lung, and Blood Institute (NHLBI) 27

Which drugs are being tested for Myeloproliferative Disorders? (3)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Cytoxan 219
Imatinib 148
Busulfan 143

Interventions as named in the registry (12)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
SQ Fludarabine 237
Cytarabine IT 143
Peripheral blood stem cell transplantation 140
Ruxolitinib IR 131
Mofetil Mycophenolate 129

Showing 5 of 12 interventions.

Start your 14-day trial Email me all 12 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Myeloproliferative Disorders trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Platelet count decreased 1,749 54
Neutrophil count decreased 1,597 31
Febrile neutropenia 1,585 133
Anemia 1,571 43
Pneumonia 1,344 155

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Myeloproliferative Disorders? (166)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
PNH clones prevalence study in ph-negative myeloproliferative neoplasms: a multicenter Italian study. Annals of hematology 2025 Yes
Genomic landscape of patients with germline RUNX1 variants and familial platelet disorder with myeloid malignancy. Blood advances 2024 Yes
Results from phase 1 of the MANIFEST clinical trial to evaluate the safety and tolerability of pelabresib in patients with myeloid malignancies. Leukemia & lymphoma 2024 Yes
TP53 in AML and MDS: The new (old) kid on the block. Blood reviews 2023 Yes
An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial. Frontiers in immunology 2023 Yes

Showing 5 of 166 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Prevalence (2)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Myeloproliferative neoplasm Annual incidence 1-9 / 100 000 Europe Not stated Exact
Myeloproliferative neoplasm Annual incidence 1-9 / 100 000 Europe Not stated Exact

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Myeloproliferative neoplasm 98274 Exact Orphadata Science knowledge files, Product 1
Myeloproliferative neoplasm 98274 Exact Orphanet Rare Disease Ontology (ORDO)

Sub-conditions in MeSH (6)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Browse all condition evidence pages